14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
TEM vs WAY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
WAY Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)
WAY Overall Winner
6-Pillar Tally: TEM 2 – 4 WAY
Matrix Metrics: TEM 3 – 7 WAY
As of Nov 17, 2026, Waystar Holding Corp. (WAY) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TEM carries a Unified Composite Score of 43.5/100 (HOLD) at $63.08 (N/M Forward P/E, -18.5% operating margin), whereas WAY carries 39.7/100 (SELL) at $27.93 (14.9x Forward P/E, 23.1% operating margin).
Composite vs. Pillar Nuance: While TEM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. WAY 39.7/100 SELL), WAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (23.1% vs. -18.5% operating margin) and revenue trajectory (+21.2% vs. +23.1% YoY).
Technical & Structure Timing Caution: TEM is currently in a Breakdown options structure phase (RSI 40.3); meanwhile WAY trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment83.0% of Rev ($1.25B)
90D Engineering Disclosures0 Published · AI Drug Discovery
WAY Moat ProfileScale & Operating Efficiency Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $5.4B market capitalization and 23.1% operating margin.
OpEx & R&D Reinvestment46.3% of Rev ($585M)
90D Engineering Disclosures0 Published
Investor FAQ TEM vs WAY Key Questions & Quantitative Answers
As of Nov 17, 2026, Waystar Holding Corp. (WAY) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TEM carries a Unified Composite Score of 43.5/100 (HOLD) at $63.08 (N/M Forward P/E, -18.5% operating margin), whereas WAY carries 39.7/100 (SELL) at $27.93 (14.9x Forward P/E, 23.1% operating margin). Composite vs. Pillar Nuance: While TEM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. WAY 39.7/100 SELL), WAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (23.1% vs. -18.5% operating margin) and revenue trajectory (+21.2% vs. +23.1% YoY). Technical & Structure Timing Caution: TEM is currently in a Breakdown options structure phase (RSI 40.3); meanwhile WAY trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TEM leads the Growth & Scale pillar: TEM posts +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin), compared with WAY at +21.2% YoY revenue growth and -5.9% YoY earnings growth on $1.26B TTM revenue (69.4% gross margin, 23.1% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), TEM cumulative revenue shifted +296.9% while WAY shifted +57.1%. In operating R&D and SG&A reinvestment, TEM deploys 83.0% of Rev ($1.25B) (0 90-day corporate R&D disclosures) versus 46.3% of Rev ($585M) (0 disclosures) for WAY.
WAY screens cheaper on headline valuation multiples. TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin), whereas WAY trades at 14.9x Forward P/E, 40.6x Trailing P/E, N/M PEG, and 5.4x EV/Revenue (20.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TEM (-37.5% ROE) versus WAY (3.7% ROE) capital efficiency.
In options market volatility and institutional positioning, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk). By comparison, WAY carries 91.8% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.33β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.